Title |
The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
|
---|---|
Published in |
European Journal of Nuclear Medicine and Molecular Imaging, November 2014
|
DOI | 10.1007/s00259-014-2949-6 |
Pubmed ID | |
Authors |
Ali Afshar-Oromieh, Eleni Avtzi, Frederik L. Giesel, Tim Holland-Letz, Heinz G. Linhart, Matthias Eder, Michael Eisenhut, Silvan Boxler, Boris A. Hadaschik, Clemens Kratochwil, Wilko Weichert, Klaus Kopka, Jürgen Debus, Uwe Haberkorn |
Abstract |
Since the introduction of positron emission tomography (PET) imaging with (68)Ga-PSMA-HBED-CC (=(68)Ga-DKFZ-PSMA-11), this method has been regarded as a significant step forward in the diagnosis of recurrent prostate cancer (PCa). However, published data exist for small patient cohorts only. The aim of this evaluation was to analyse the diagnostic value of (68)Ga-PSMA-ligand PET/CT in a large cohort and the influence of several possibly interacting variables. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 408 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 2 | <1% |
United States | 2 | <1% |
Germany | 1 | <1% |
Canada | 1 | <1% |
Sweden | 1 | <1% |
Spain | 1 | <1% |
Denmark | 1 | <1% |
Unknown | 399 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 68 | 17% |
Student > Ph. D. Student | 44 | 11% |
Other | 37 | 9% |
Student > Postgraduate | 34 | 8% |
Student > Bachelor | 34 | 8% |
Other | 102 | 25% |
Unknown | 89 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 187 | 46% |
Chemistry | 29 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 17 | 4% |
Physics and Astronomy | 12 | 3% |
Nursing and Health Professions | 9 | 2% |
Other | 46 | 11% |
Unknown | 108 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2024.
All research outputs
#2,627,526
of 26,017,215 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#190
of 3,565 outputs
Outputs of similar age
#34,717
of 375,561 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#2
of 31 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,565 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 375,561 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.